Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma

a phase-II study from Fondazione Italiana Linfomi (FIL)

Flavia Salvi, Stefano Luminari, Alessandra Tucci, Stefania Massidda, Anna Marina Liberati, Caterina Stelitano, Manuela Zanni, Alessandro Re, Riccardo Centurioni, Roberto Freilone, Gerardo Musuraca, Luca Nassi, Caterina Patti, Annalisa Arcari, Monica Tani, Alessandro Pulsoni, Vincenzo Pavone, Stefano Volpetti, Annalisa Peli, Andrea Evangelista & 3 others Michele Spina, Marco Ladetto, Francesco Merli

Research output: Contribution to journalArticle

Abstract

This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I–IIA and IIB–IV patients were treated with three courses of MBVD plus radiotherapy, or six courses of MBVD, respectively, plus radiotherapy limited to bulky or residual disease areas. The primary endpoints were CR rate and the rate of cardiac events. Forty-seven patients were enrolled. Median age was 75 years, 13 had stage I–II disease. Overall, CR was achieved by 36 patients (77%, 95% CI: 62–88), 100% and 68% in stage I–II and III–IV, respectively. With a median follow-up of 40 months (IQR: 36–45). Three-year overall survival (OS) and progression-free survival (PFS) were 70% and 43%, respectively. Cardiac events grades 3–5 were reported in two patients. In conclusion, MBVD’s activity and safety profile was comparable to historical ABVD data.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Dacarbazine
Vinblastine
Bleomycin
Hodgkin Disease
Radiotherapy
Doxorubicin
Disease-Free Survival
liposomal doxorubicin
Safety
Survival

Keywords

  • cardiotoxicity
  • co-morbidity
  • elderly
  • Hodgkin lymphoma
  • liposomal doxorubicin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma : a phase-II study from Fondazione Italiana Linfomi (FIL). / Salvi, Flavia; Luminari, Stefano; Tucci, Alessandra; Massidda, Stefania; Liberati, Anna Marina; Stelitano, Caterina; Zanni, Manuela; Re, Alessandro; Centurioni, Riccardo; Freilone, Roberto; Musuraca, Gerardo; Nassi, Luca; Patti, Caterina; Arcari, Annalisa; Tani, Monica; Pulsoni, Alessandro; Pavone, Vincenzo; Volpetti, Stefano; Peli, Annalisa; Evangelista, Andrea; Spina, Michele; Ladetto, Marco; Merli, Francesco.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

Salvi, F, Luminari, S, Tucci, A, Massidda, S, Liberati, AM, Stelitano, C, Zanni, M, Re, A, Centurioni, R, Freilone, R, Musuraca, G, Nassi, L, Patti, C, Arcari, A, Tani, M, Pulsoni, A, Pavone, V, Volpetti, S, Peli, A, Evangelista, A, Spina, M, Ladetto, M & Merli, F 2019, 'Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)', Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2019.1608529
Salvi, Flavia ; Luminari, Stefano ; Tucci, Alessandra ; Massidda, Stefania ; Liberati, Anna Marina ; Stelitano, Caterina ; Zanni, Manuela ; Re, Alessandro ; Centurioni, Riccardo ; Freilone, Roberto ; Musuraca, Gerardo ; Nassi, Luca ; Patti, Caterina ; Arcari, Annalisa ; Tani, Monica ; Pulsoni, Alessandro ; Pavone, Vincenzo ; Volpetti, Stefano ; Peli, Annalisa ; Evangelista, Andrea ; Spina, Michele ; Ladetto, Marco ; Merli, Francesco. / Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma : a phase-II study from Fondazione Italiana Linfomi (FIL). In: Leukemia and Lymphoma. 2019.
@article{0e36df6b597d44eba9d53bc8457de6e3,
title = "Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)",
abstract = "This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I–IIA and IIB–IV patients were treated with three courses of MBVD plus radiotherapy, or six courses of MBVD, respectively, plus radiotherapy limited to bulky or residual disease areas. The primary endpoints were CR rate and the rate of cardiac events. Forty-seven patients were enrolled. Median age was 75 years, 13 had stage I–II disease. Overall, CR was achieved by 36 patients (77{\%}, 95{\%} CI: 62–88), 100{\%} and 68{\%} in stage I–II and III–IV, respectively. With a median follow-up of 40 months (IQR: 36–45). Three-year overall survival (OS) and progression-free survival (PFS) were 70{\%} and 43{\%}, respectively. Cardiac events grades 3–5 were reported in two patients. In conclusion, MBVD’s activity and safety profile was comparable to historical ABVD data.",
keywords = "cardiotoxicity, co-morbidity, elderly, Hodgkin lymphoma, liposomal doxorubicin",
author = "Flavia Salvi and Stefano Luminari and Alessandra Tucci and Stefania Massidda and Liberati, {Anna Marina} and Caterina Stelitano and Manuela Zanni and Alessandro Re and Riccardo Centurioni and Roberto Freilone and Gerardo Musuraca and Luca Nassi and Caterina Patti and Annalisa Arcari and Monica Tani and Alessandro Pulsoni and Vincenzo Pavone and Stefano Volpetti and Annalisa Peli and Andrea Evangelista and Michele Spina and Marco Ladetto and Francesco Merli",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2019.1608529",
language = "English",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma

T2 - a phase-II study from Fondazione Italiana Linfomi (FIL)

AU - Salvi, Flavia

AU - Luminari, Stefano

AU - Tucci, Alessandra

AU - Massidda, Stefania

AU - Liberati, Anna Marina

AU - Stelitano, Caterina

AU - Zanni, Manuela

AU - Re, Alessandro

AU - Centurioni, Riccardo

AU - Freilone, Roberto

AU - Musuraca, Gerardo

AU - Nassi, Luca

AU - Patti, Caterina

AU - Arcari, Annalisa

AU - Tani, Monica

AU - Pulsoni, Alessandro

AU - Pavone, Vincenzo

AU - Volpetti, Stefano

AU - Peli, Annalisa

AU - Evangelista, Andrea

AU - Spina, Michele

AU - Ladetto, Marco

AU - Merli, Francesco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I–IIA and IIB–IV patients were treated with three courses of MBVD plus radiotherapy, or six courses of MBVD, respectively, plus radiotherapy limited to bulky or residual disease areas. The primary endpoints were CR rate and the rate of cardiac events. Forty-seven patients were enrolled. Median age was 75 years, 13 had stage I–II disease. Overall, CR was achieved by 36 patients (77%, 95% CI: 62–88), 100% and 68% in stage I–II and III–IV, respectively. With a median follow-up of 40 months (IQR: 36–45). Three-year overall survival (OS) and progression-free survival (PFS) were 70% and 43%, respectively. Cardiac events grades 3–5 were reported in two patients. In conclusion, MBVD’s activity and safety profile was comparable to historical ABVD data.

AB - This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I–IIA and IIB–IV patients were treated with three courses of MBVD plus radiotherapy, or six courses of MBVD, respectively, plus radiotherapy limited to bulky or residual disease areas. The primary endpoints were CR rate and the rate of cardiac events. Forty-seven patients were enrolled. Median age was 75 years, 13 had stage I–II disease. Overall, CR was achieved by 36 patients (77%, 95% CI: 62–88), 100% and 68% in stage I–II and III–IV, respectively. With a median follow-up of 40 months (IQR: 36–45). Three-year overall survival (OS) and progression-free survival (PFS) were 70% and 43%, respectively. Cardiac events grades 3–5 were reported in two patients. In conclusion, MBVD’s activity and safety profile was comparable to historical ABVD data.

KW - cardiotoxicity

KW - co-morbidity

KW - elderly

KW - Hodgkin lymphoma

KW - liposomal doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=85068729520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068729520&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1608529

DO - 10.1080/10428194.2019.1608529

M3 - Article

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -